Cefepime: Nursing Drug Guide, Neurotoxicity & Renal Dosing
Broad-spectrum IV cephalosporin for serious infections — but missed renal dose adjustment can cause reversible yet life-threatening neurotoxicity (confusion, myoclonus, seizures). Verify creatinine clearance before every course, infuse over 30 minutes, and stop at the first neurologic red flag.
Cefepime can cause life-threatening neurotoxicity—confusion, hallucinations, myoclonus, seizures, and nonconvulsive status epilepticus—especially when creatinine clearance is 60 mL/min or less and the dose or interval is not adjusted. Most reported cases occurred in patients with renal impairment given unadjusted doses, including older adults. Before the first dose and after any change in renal function, verify pharmacy-adjusted orders against current CrCl. If new neurologic symptoms appear, hold cefepime, notify the prescriber, and institute supportive care; hemodialysis may aid removal in renal impairment per labeling.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Recalculate creatinine clearance before every cefepime course and after acute kidney injury, dehydration, or diuretic changes—then confirm the MAR matches Table 2 renal adjustments. New confusion or myoclonus in a patient on cefepime is a hold-and-escalate event until neurotoxicity and supratherapeutic exposure are ruled out.
Most common brand names
Cefepime is available generically and as Maxipime (cefepime hydrochloride). Baxter labeling also supplies premixed Galaxy containers (1 g in 50 mL; 2 g in 100 mL). Verify strength, volume, and renal-adjusted interval on the MAR—not just the antibiotic name.
Why we give it — Indications
Cefepime is a broad-spectrum IV cephalosporin for serious infections when gram-negative coverage (including many Pseudomonas strains) is needed—often combined with an anaerobic agent such as IV metronidazole for labeled complicated intra-abdominal infections. Nurses most often see it for hospital-acquired or complicated infections after cultures are sent.
| Use | Detail |
|---|---|
| Pneumonia | Mild to moderate community-acquired pneumonia (1 g q12h) and moderate-to-severe pneumonia due to P. aeruginosa (2 g q8h) per labeling |
| Urinary tract infection | Uncomplicated and complicated urinary tract infection including pyelonephritis (0.5–1 g q12h for 7–10 days) |
| Skin and soft tissue | Complicated cellulitis (2 g q12h) when IV cephalosporin therapy is ordered |
| Febrile neutropenia / empiric therapy | Empiric gram-negative coverage while awaiting blood cultures—often combined with other agents per protocol |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Cefepime inhibits bacterial cell-wall synthesis (beta-lactam). It has extended gram-negative activity compared with earlier cephalosporins. The drug is eliminated primarily by the kidneys; when CrCl falls, serum levels rise and CNS penetration increases—raising neurotoxicity risk if dosing is not reduced or intervals lengthened.
Dosing overview
Standard adult regimens apply when CrCl is greater than 60 mL/min. When CrCl is 60 mL/min or less, adjust dose and/or interval per Table 2 in Baxter labeling—this is the primary nursing safety checkpoint for neurotoxicity prevention.
Table 2 (Baxter label) adult maintenance examples when CrCl is 60 mL/min or less — verify the exact regimen against the prescribing table for each ordered nominal dose tier.
| Creatinine clearance | Example shifts (consult full Table 2 for all dose ladders) |
|---|---|
| > 60 mL/min | Standard interval per Table 1 (e.g., 2 g every 12 h mild–moderate UTI up to 2 g every 8 h for selected severe infections). |
| 30–60 | Intervals lengthen—for the high-frequency column, labeling maps 500 mg q12 h→q24 h, 1 g q12 h→q24 h, 2 g q12 h→q24 h, and 2 g q8 h→q12 h. |
| 11–29 | Further prolonged intervals—for the same ladders, labeling maps toward 500–2000 mg daily divided per row (e.g., 2 g q8 h→q24 h). |
| < 11 | Lowest tier schedules—for the same ladders, labeling maps doses down to 250–1000 mg daily per row. |
| CAPD | May use labeled strengths at extended intervals—for many columns, labeling uses every 48 h dosing. |
| Hemodialysis | ≈68% removal in a 3-hour session; label-guided loading then reduced maintenance—for many regimens labeling uses 1 g on day 1 then 500 mg every 24 h; febrile neutropenia dosing differs. Give after dialysis on dialysis days. |
On a small screen, swipe or scroll sideways to see the full table.
Estimate CrCl when only serum creatinine is available (Cockcroft-Gault per labeling). Trend eGFR and creatinine during diuretic therapy, contrast, or sepsis-related acute kidney injury.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact pharmacy for the next safe administration time when renal function is borderline.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Administration | IV over ≈30 minutes | Program pump for full duration; not a bolus antibiotic |
| Half-life (healthy adults) | ≈2 hours (mean) | Prolonged in renal impairment—drives interval extension |
| Elimination | ≈85% unchanged in urine | Renal dose adjustment mandatory at CrCl ≤60 mL/min |
| Hemodialysis removal | ≈68% removed in 3-hour session | Redose after HD per Table 2; coordinate timing with dialysis unit |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm beta-lactam allergy history (penicillin, cephalosporin, carbapenem) and prior immediate hypersensitivity
- Calculate or verify CrCl/eGFR; compare MAR dose and interval to renal adjustment table—especially in chronic kidney disease or rising creatinine
- Perform medication reconciliation for concurrent nephrotoxins or IV incompatibilities
Contraindications
- Immediate hypersensitivity to cefepime, cephalosporins, penicillins, or other beta-lactams
- Dextrose-containing solutions contraindicated in patients with known corn allergy (Galaxy container excipient)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Furosemide / dehydration | Volume depletion and AKI raise cefepime levels and neurotoxicity risk | Monitor I&O, creatinine, mental status; request dose re-evaluation if renal function worsens |
| Aminoglycosides | Increased nephrotoxicity and ototoxicity potential with high aminoglycoside doses | Monitor renal function and levels per protocol; separate administration when possible |
| Probenecid | May increase cefepime exposure | Notify pharmacist if probenecid is added during cefepime therapy |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Intravenous only. Infuse over approximately 30 minutes per FDA labeling.
- Thaw frozen Galaxy containers at room temperature or under refrigeration—do not force-thaw in water baths or microwaves
- Inspect for particulates, leaks, and discoloration before hanging; follow IV infusion pump setup and independent double-check for high-risk IV antibiotics
- Do not add cefepime to the same line or solution as vancomycin, metronidazole, aminoglycosides, or ampicillin concentrations >40 mg/mL—administer separately when concurrent therapy is ordered
- Use high-alert medication administration practices when verifying mg, bag volume, pump rate, and renal-adjusted schedule
Expected therapeutic response
- Defervescence and improving clinical status for the treated infection (when paired with source control and culture-directed therapy)
- Down-trending inflammatory markers and culture clearance when susceptibilities confirm cefepime activity
- Stable neurologic baseline—cefepime should not cause new confusion or myoclonus when appropriately dosed
Red flags — Stop and act
Hold cefepime and escalate immediately for neurologic toxicity, severe hypersensitivity, or fulminant CDAD.
- New altered mental status, hallucinations, aphasia, myoclonus, seizures, or nonconvulsive status epilepticus—especially with renal impairment or unadjusted dosing
- Urticaria, bronchospasm, hypotension, or other signs of anaphylaxis during or after infusion
- Generalized rash, mucosal lesions, or blistering (possible severe cutaneous reaction)
- Profuse watery diarrhea with abdominal pain or fever during or after antibiotic therapy (evaluate for CDAD)
- Creatinine rise, oliguria, or missed renal dose adjustment on the MAR when neuro symptoms appear
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Rash, pruritus | Common at higher doses (≥1%) | Monitor progression; discontinue if serious skin reaction suspected |
| Diarrhea, nausea, vomiting | Common (≥1% at 2 g q8h) | Assess hydration; evaluate for CDAD if profuse or bloody |
| Neurotoxicity | Serious; often with renal impairment | Hold drug, notify prescriber, supportive care, consider hemodialysis per labeling |
| Positive Coombs test | Laboratory finding | Document; correlate with hemolysis symptoms if present |
| Increased AST/ALT, PT/PTT | Reported in trials | Trend hepatic panel and coagulation studies per protocol |
| Local infusion reactions | Phlebitis, pain at site | Assess IV site; rotate per policy; report persistent inflammation |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
No specific antidote is listed in Baxter cefepime labeling. Overdose symptoms mirror neurotoxicity: encephalopathy, myoclonus, seizures, and neuromuscular excitability. Accidental overdosing has occurred when large doses were given to patients with impaired renal function.
Management
- Discontinue cefepime and provide supportive care with close neurologic monitoring
- In renal impairment, hemodialysis (not peritoneal dialysis alone) is recommended to aid removal
- Contact prescriber, pharmacist, and local poison control / toxicology services per facility protocol
Look-alike / sound-alike and error prevention
- Cefepime vs ceftazidime vs cefazolin—fourth-gen vs third-gen vs first-gen cephalosporins with different spectra and renal schedules
- Cefepime vs cefTRIAXone—similar syllables; verify generic name on vial and MAR
- 2 g q8h vs 2 g q24h—renal adjustment errors look like small MAR edits but dramatically change exposure
- Galaxy 2 g/100 mL bag—administer entire bag only when full dose is ordered; partial doses need pharmacy preparation
- Concurrent vancomycin + cefepime—Y-site incompatibility; run sequentially with line flush per pharmacy
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Renal recheck triggers | New diuretics, contrast, hypotension, rising creatinine—request pharmacy re-evaluation before next dose |
| Neuro checks | Baseline and daily mental status in older adults and CKD; myoclonus or word-finding trouble = stop and escalate |
| Infusion time | ≈30 minutes; reprogram pump if rate error discovered mid-infusion |
| Frozen bags | Room-temp thaw; gentle swirl; discard if cloudiness or precipitate persists |
| Commonly missed | Standard q8h order left unchanged after AKI; home dialysis schedule not communicated to pharmacy |
| Ask pharmacy when | CrCl ≤60, HD/CAPD patient, suspected neurotoxicity, or incompatible IV meds on same line |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Higher baseline renal impairment; labeling reports serious neurotoxicity in geriatric patients given unadjusted doses |
| Renal impairment / dialysis | Mandatory Table 2 adjustment at CrCl ≤60; HD dosing timed after dialysis session |
| Penicillin allergy history | Cross-reactivity up to 10%; obtain allergy clarification before first dose |
| Critical illness with fluctuating CrCl | Sepsis, shock, and diuretics alter renal function daily—do not assume admission CrCl still applies |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Renal function (creatinine, basic metabolic panel) at baseline and during therapy when CrCl may change
- Neurologic status (orientation, speech, myoclonus, seizure activity) at least each shift—more often if renal impairment
- Infection markers (temperature, WBC, culture results) and stool pattern for CDAD
- IV site and infusion completion times
Document
- CrCl/eGFR used to verify dose, actual dose infused, rate, and time
- Any held doses with prescriber/pharmacist notification and neuro symptom timeline
- Patient teaching on reporting diarrhea, rash, or confusion
Patient teaching
- Report sudden confusion, twitching, trouble speaking, or seizures immediately—even if the infection seems to be improving
- Report severe or persistent diarrhea, especially if bloody or accompanied by abdominal pain
- Report rash, itching, swelling, or trouble breathing during infusion
- IV antibiotics require full infusion time; notify the nurse if the pump alarms or the site burns
The Hold Rule
- Any new neurotoxicity sign (confusion, myoclonus, seizure, nonconvulsive status epilepticus)
- CrCl ≤60 with an order that does not match renal adjustment table
- Known or suspected beta-lactam anaphylaxis or serious cutaneous reaction
- Profuse CDAD-type diarrhea pending evaluation
- Pump rate error delivering dose faster than 30-minute infusion without prescriber guidance
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Cefepime is often ordered on sepsis pathways where renal function changes hourly. Build CrCl verification into antibiotic time-outs alongside culture review—neurotoxicity is preventable when dose and interval match kidney function.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right renal-adjusted interval
- Compare today’s creatinine/CrCl to the value used when the order was written
- Independent double-check bag strength (1 g/50 mL vs 2 g/100 mL) and pump duration (≈30 min)
- Confirm incompatible agents will be administered separately
2. High-alert and safety badge
Renal neurotoxicity risk — treat dose/interval verification as high-stakes even when not on institutional high-alert listBaxter labeling warns that unadjusted dosing in renal impairment has caused fatal encephalopathy and seizures. Use the same rigor as high-alert IV antibiotics when CrCl is ≤60.
3. Clinical workflow: hold and question rules
- If neuro symptoms appear, hold the next dose and page prescriber/pharmacy before restarting—symptoms may reverse after discontinuation and/or hemodialysis
- If creatinine rises mid-course, pause until pharmacy recalculates—do not continue q8h by habit
- Escalate CDAD suspicion early; do not automatically restart cefepime if alternative therapy is needed
4. Critical teach-back questions
- “What new symptoms should you report while on this IV antibiotic?” (Confusion, twitching, severe diarrhea, rash, breathing trouble.)
- “Why might your nurse ask about kidney function before each dose?” (Cefepime is cleared by the kidneys; dose must change when kidney function falls.)
5. Care coordination
Pharmacist: Renal dose verification, HD/CAPD scheduling, Y-site compatibility, and alternative agents if neurotoxicity occurs
Prescriber / nephrology: Notify for rising creatinine, dialysis timing questions, or need to switch antibiotic class after serious reaction
🧠 Quick mental checklist
- What is this patient’s current CrCl and does the MAR interval match Table 2?
- Has creatinine changed since the order was written?
- Any new confusion, myoclonus, or speech change since the last dose?
- Are vancomycin or metronidazole scheduled on the same line without pharmacy clearance?
- If neurotoxicity suspected, is cefepime held and prescriber/pharmacy notified?
Cefepime NCLEX practice questions
Practice NCLEX-style clinical judgment practice for cefepime using a tabbed inpatient case (MAR, labs, I&O, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency sorting, renal dosing judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Cefepime 2 g IV q8h — given 0600, 1400; 2200 due
- Vancomycin IV (separate line) per pharmacy — trough pending
- Furosemide 40 mg IV daily — 0800 given
- Pharmacy renal note on chart: CrCl 26 mL/min — standard q8h schedule not adjusted on MAR
- Admission CrCl ≈ 48 mL/min; today creatinine 2.6 mg/dL (was 1.9), estimated CrCl 26 mL/min
- BMP: K 4.8 mEq/L; BUN 48 mg/dL
- Blood cultures: gram-negative rods in 1/2 bottles (preliminary)
- Previous 24 h: intake 1.8 L; output 650 mL (≈27 mL/h average)
- Weight up 1.4 kg; mild dependent edema; patient reports dry mouth
- 0800–1600: output 120 mL despite diuretic
- 1545: 82-year-old with hospital-acquired pneumonia; intermittent confusion overnight attributed to “ICU delirium”
- 1630: New bilateral hand myoclonus during conversation; oriented only to person
- 1640: Nurse reviewing MAR, labs, and I&O before 2200 cefepime dose
Answer key & rationale
Frequently asked questions
When must nurses adjust cefepime for renal function?
Prescribing information requires dose adjustment when creatinine clearance is 60 mL/min or less. The maintenance schedule depends on the ordered dose and interval—for example, 2 g every 8 hours becomes 2 g every 12 hours when CrCl is 30–60 mL/min. Recalculate after acute kidney injury, dehydration, or new dialysis. Verify pharmacy-adjusted orders before administration.
What neurotoxicity signs should make a nurse hold cefepime?
Hold and escalate for new confusion, hallucinations, stupor, coma, aphasia, myoclonus, seizures, or nonconvulsive status epilepticus—especially in older adults or patients with rising creatinine. Labeling states most cases occurred with renal impairment and missed dose adjustment. Discontinue cefepime per prescriber direction; hemodialysis may aid removal in renal impairment.
How should cefepime be given IV?
Administer cefepime intravenously over approximately 30 minutes per Baxter labeling. Do not force-thaw premixed frozen bags in water baths or microwaves. Cefepime should not be added to the same solution as vancomycin, metronidazole, or aminoglycosides—administer separately when concurrent therapy is ordered.
Is cefepime safe in penicillin-allergic patients?
Cefepime is contraindicated after immediate hypersensitivity to cefepime, cephalosporins, penicillins, or other beta-lactams. Cross-hypersensitivity may occur in up to 10% of patients with penicillin allergy history. Obtain allergy history before the first dose and stop the infusion if an allergic reaction occurs.
What is the antidote for cefepime overdose?
No specific antidote is listed in the reviewed prescribing information. Overdose management is supportive. In renal impairment, hemodialysis—not peritoneal dialysis—is recommended to aid removal. Symptoms include encephalopathy, myoclonus, and seizures. Contact local poison control or toxicology services per facility protocol.
References
-
U.S. National Library of Medicine. Cefepime injection — Full prescribing information. DailyMed (Baxter).https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be5f8ca6-7232-423a-a2d5-cccb7abe7921
-
Pfizer Inc. Maxipime (cefepime) prescribing information.https://labeling.pfizer.com/ShowLabeling.aspx?id=4383
-
Drugs and Lactation Database (LactMed). Cefepime. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM46/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.